Efzimfotase alfa: clear pediatric bone‑health benefit; adult gains concentrated in pediatric‑onset HPP
Efzimfotase alfa, a next‑generation enzyme replacement therapy from AstraZeneca Rare Disease, produced a clear, statistically significant bone‑health signal in treatment‑naïve…